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A B S T R A C T 
 
In the present work, the development of a transdermal nanocarrier drug delivery system with 
potential for the treatment of psychiatric disorders, such as schizophrenia and bipolar disorder, is 
described. Lipid nanocarriers, encompassing various solid:liquid lipid compositions were formulated and 
assessed as potential nanosystems for transdermal delivery of olanzapine. A previously optimised method 
of hot high pressure homogenization (HPH) was adopted for the production of the lipid nanocarriers, 
which comprised solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC) and nanoemulsions 
(NE). 
Precirol® was selected as the solid lipid for progression of studies. SLN exhibited the best 
performance for transdermal delivery of olanzapine, based on in vitro realease and permeation studies, 
coupled with results from physicochemical characterization of several solid:liquid lipid formulations. 
Stability tests, performed to give an indication of long-term storage behavior of the formulations, were in 
good agreement with previous studies for the best choice of solid:liquid lipid ratio.  
Overall, these findings highlight the SLN-based formulation as promising for the further 
inclusion in and production of transdermal patches, representing an innovative therapeutic approach. 
 
Keywords: Lipid nanocarriers; Nanostructured lipid carriers; Solid lipid nanoparticles; Nanoemulsions; 
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1. Introduction 
The skin is the human body’s largest organ and a key barrier in transdermal drug delivery (1, 2). 
The skin consists of three main layers: the epidermis, dermis, and hypodermis. The epidermis, in 
particular the outermost layer known as the stratum corneum, is the main biological barrier in drug 
delivery. The stratum corneum is a highly lipophilic membrane comprising tightly packed corneocyte 
cells embedded within intercellular lipids (3). It acts as an excellent natural barrier, which poses problems 
for transdermal delivery systems limiting the number of drugs that can cross it, to achieve a therapeutic 
effect. 
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Transdermal drug delivery is used in the treatment of a range of conditions, such as smoking 
cessation (nicotine patches), pain management (fentanyl patches) and angina (glyceryl trinitrate patches). 
However, other therapeutic areas remains largely unexplored. In the present work, the potential of 
transdermal delivery of olanzapine, in the treatment of psychiatric disorders such as, schizophrenia and 
bipolar disorder, was investigated. Olanzapine is currently available as an injection (intramuscular) and in 
oral dosage forms. It is usually administered as one or two daily doses, with an overall dosage of 5–
10 mg/day. Despite being an effective antipsychotic, its low oral bioavailability and low compliance 
amongst psychiatric patients are serious problems, which modern pharmaceutical technology aims to 
overcome by developing a transdermal drug delivery system (4). Olanzapine is a leading candidate for 
transdermal drug delivery, due to its lipophilic nature (log P 2.8), low molecular weight (MW=312.4) and 
low melting point (195◦C) (5). Apart from the physicochemical properties, its poor oral bioavailability 
and extensive first-pass metabolism (approximately 40% of the dose is metabolized before reaching the 
systemic circulation), ideally suit this drug for transdermal administration (6). This route of 
administration of olanzapine is suitable for patients who cannot tolerate oral dosage forms and does not 
come with the drawbacks of drug delivery via injection, such as patient compliance, risk of infection and 
invasive nature, among others (4). 
Previous work on transdermal delivery of olanzapine is limited. Nanocarrier-entrapped 
olanzapine has previously been formulated by Aggarwal et al., who looked into the effects of different 
permeation enhancers in transdermal drug delivery systems (TDDS) of olanzapine (4). Others have 
looked at the effect of the lipid matrix, on the entrapment efficiency of olanzapine as well as its release 
behaviour (7). Research into coencapsulated olanzapine-simvastatin formulations for transdermal 
delivery, has also been explored (8). Currently, the prospect of olanzapine delivery via transdermal 
patches, is a relatively new area of research, which requires additional research and optimisation before 
clinical evaluation and potential commercialization. 
This work focuses on the use of solid lipid nanoparticles (SLNs), nanostructured lipid carriers 
(NLCs) and nanoemulsions (NE), as potential TDDS of olanzapine. The nature of lipid nanoparticles 
confers them distinct advantages over conventional nanocarrier systems, such as excellent tolerability, 
physical stability, and the possibility to modulate drug release (9). 
Lipid nanoparticles can be produced using various methods, including high shear 
homogenization (10), nanoprecipitation (11), spray drying (12), solvent emulsification–evaporation (13) 
and by high pressure homogenization (HPH) (14). Due to previously optimized preparation strategies, 
where better performance with respect to drug loading and in vitro permeation rate was attained (Vitorino 
et al. 2014), a hot HPH method was employed in this study. Moreover, this established simple and very 
cost-effective technique does not have the scale-up problems associated with some other nanoparticle 
production methods (15). 
Physicochemical parameters, such as particle size, zeta potential, polydispersity index and 
entrapment efficiency, can have a significant effect on the nanocarrier system and its in vitro performance 
in release/permeation studies. Characterisation of the lipid nanoparticles is therefore an essential step, in 
order to select for the best candidate, for transdermal delivery of olanzapine.  
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The aim of this study is to identify the best solid lipid candidate for lipid nanocarrier (LN) 
formulation (i.e. the one which provides the best target product quality profile for administration through 
the skin) and to systematically assess how the composition of nanoparticles, in terms of solid:liquid lipid 
ratio, affects different physicochemical parameters. A combination of in vitro release and permeation 
studies, whilst considering previously highlighted parameters, should allow selection of a solid:liquid 
lipid ratio best suited for transdermal drug delivery of olanzapine. 
 
2. Materials and methods 
2.1. Materials 
Olanzapine was obtained from Zhejiang Myjoy (Hangzhou, China). Compritol® 888 ATO 
(glycerylbehenate, melting point: 71–74 ◦C), stearic acid (melting point: 70 ◦C) and Precirol® ATO 5 
(glyceryl palmitostearate, melting point: 53–56 ◦C) were provided by Gattefossé (Saint-Priest, Cedex, 
France). Oleic acid, polysorbate 80 (Tween® 80) and phosphate buffered saline (PBS) pH 7.4, were 
purchased from Sigma-Aldrich (Sintra, Portugal). All other solvents and reagents were of analytical or 
high performance liquid chromatography (HPLC) grade. 
 
2.2. Preparation of lipid nanocarriers (LN) by high pressure homogenisation 
Hot high pressure homogenisation (HPH) was used to produce the lipid nanoparticles, 
comprising SLNs, NLCs and nanoemulsions. A concentration of 7.5 % w/V of the lipid phase (solid 
and/or liquid lipid) was melted at 10 ºC higher than the solid lipid melting point. This was then mixed 
with 30 mL of 3% (w/V) Tween® 80 in water, at the same temperature (80ºC), and pre-emulsified for 1 
min, using an Ultra-Turrax X1020 (Ystral GmbH, Dottingen, Germany) at 25,000 rpm. The pre-emulsion 
was then put through hot HPH at 1000 bar for 2.5 min using an Emulsiflex®-C3 (Avestin Inc, Ottawa, 
Canada). The resultant dispersion was then stored at 4 ◦C to form the LN. 
For olanzapine-loaded formulations, 80 mg of olanzapine was incorporated into the melted lipid 
phase. This amount was used following preliminary solubility studies. NLC formulations of varying solid 
lipid, were prepared according to the ratios shown in Table 1. 
 
Table 1. Composition of NLCs prepared from different solid lipids; Precirol®, Compritol® and stearic 
acid.  
Formulation (50:50) Amount of solid lipid (g) Amount of liquid lipid (g) 
Precirol®:oleic acid 1.125 1.125 
Compritol®: oleic acid 1.125 1.125 
Stearic acid:oleic acid 1.125 1.125 
 
The amounts of Precirol® and oleic acid used to carry out investigations, after the selection of 
solid lipid, are shown in Table 2. The term lipid nanocarrier/s (LN) encompasses all physical forms. 
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Table 2. Ratios of Precirol®:oleic acid used in formulations. The physical form of nanocarrier produced 
by this methodology resulted in the production of SLNs, NLCs or NE, depending on the ratio of 
Precirol:oleid acid.  
Formulation 
(Precirol®:oleic acid ratio) 
Amount of solid lipid 
(g) 
Amount of liquid lipid 
(g) 
Type of 
nanocarrier 
100:0 2.250 0.000 SLN 
75:25 1.688 0.563 NLC 
50:50 1.125 1.125 NLC 
25:75 0.563 1.688 NLC 
0:100 0.000 2.250 NE 
 
Note that although NLCs are generally obtained from blends of solid with liquid lipids, 
preferably in a ratio of 70:30 up to a ratio of 99.9:0.1 (16), recent studies have reported the use of lower 
solid to liquid lipid ratio (e.g. 50:50 ratio (17), or even lower (18, 19)) without compromise of their solid 
nature.  
 
 
2.3. Particle size analysis 
Dynamic light scattering (DLS) was used to determine the mean hydrodynamic diameter and 
polydispersity index (PI). The PI measures the width of the size distribution. These were measured using 
a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) set at a detection angle of 173◦ at 25◦C. 
Samples were appropriately diluted in ultra-purified water (pH ≈ 5.5) and analysed three times each. 
Cumulants method was used for data analysis. Results are shown as mean ± standard deviation. 
 
2.4. Zeta potential 
Zeta potential (ZP) reflects the charge on the particle surface, giving an indication of physical 
stability of the system. ZP was determined using a Zetasizer Nano ZS (Malvern Instruments, Malvern, 
UK) set at a temperature of 25 ◦C. Samples were diluted suitably in ultra-purified water and analysed 
three times each. The Helmholtz-Smoluchowsky equation was used for ZP calculation. 
 
2.5. Occlusive effect studies 
To study the effect of the LN formulations on skin occlusivity, in vitro occlusion tests, modified 
from de Vringer and de Ronde were performed (20, 21). Beakers (50 mL) were filled with 30 g of water 
and covered with filter paper (cellulose acetate filter, 90 mm, Whatman nº6, cutoff size 3 μm), and sealed. 
600 μL of LN formulation was spread homogeneously across the filter paper, covering the entire surface 
area of 15.9 cm2. These were then stored at 32 ºC for 48 h to simulate skin surface temperature. The 
weight of water remaining in the beakers, was weighed at time intervals of 24 and 48 h. Beakers in the 
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same conditions, but covered with 600 μL of water were used as a reference. The tests were conducted in 
triplicate for each formulation. The occlusion factor (F) was calculated according to Eq. 1; 
F = (A-B / A) x 100                                                                         Eq. 1 
where A is the water loss without formulation applied (reference) and B is the water loss with LN 
formulation applied. A value of 0 indicates no occlusive effect compared to the reference, while a value 
of 100 corresponds to maximum occlusiveness. 
 
2.6. Entrapment efficiency and drug loading 
Entrapment efficiency, relates to the amount of drug that can be incorporated in LN, either 
within the nanoparticle or adsorbed onto its surface. Olanzapine entrapment efficiency was determined 
indirectly, by measuring the concentration of free drug within the aqueous phase of the LN dispersion. An 
ultrafiltration-centrifugation method was performed, using centrifugal filters (Amicon® Ultra-4, 
Millipore, Germany) with a molecular weight cutoff 1000 kDa. 500 μL of the formulations were pipette 
into the top chamber of the centrifuge filter and centrifuged for 45 min at 3000 x g at 4 ◦C. 400 μL of the 
aqueous dispersion phase was collected from the outer centrifugal filter after separation and combined 
with 400 μL of mobile phase for drug quantification. The mobile phase comprised ammonium acetate 
(0.02 M in water), methanol and acetonitrile in the volume ratio 30:35:35. The total amount of drug 
present in the system was also quantified. For that, 50 μL of the nanoparticle formulation was diluted into 
1950 μL of the mobile phase and heated at 60 ◦C for 15 min. The formulation was then centrifuged for 15 
min at 12600 x g and the supernatant filtered using a 0.22 μm membrane for drug quantification. All drug 
quantification was carried out by high performance liquid chromatography (HPLC) as described in 
Section 2.10. Entrapment efficiency (EE) and drug loading (DL) were calculated using Eq. 2 and Eq. 3; 
 
% EE = (Wtotal drug – Wfree drug / Wtotal drug ) x 100                 Eq. 2  
% DL = (Wtotal drug – Wfree drug / Wlipid ) x 100         Eq. 3 
where Wtotal drug is the amount of olanzapine determined in the whole system, Wfree drug is the amount of 
free drug determined in the aqueous phase after separation of the nanoparticles and Wlipid is the weight of 
the lipid phase. 
 
2.7. In vitro release studies 
In vitro release studies were conducted using static Franz diffusion cells (PermeGear, Inc., PA, 
USA) with a diffusion area 0.636 cm2 and a receptor compartment of 5 mL, as described by Vitorino et 
al. (8). Tests were performed using a dialysis cellulose membrane (MWC0 ~12,000, avg. flat width 33 
mm, D9652, Sigma-Aldrich, Sintra, Portugal), which was clamped between the donor and receptor 
compartments. The receptor compartment contained a medium of 70% PBS (pH=7.4) and 30% ethanol to 
ensure sink conditions. The receptor medium was stirred at 600 rpm and maintained at 37 ◦C, ensuring a 
temperature of 32 ◦C at the skin surface in order to mimic skin conditions. 400 μL of the formulations 
were applied to the donor compartment and to prevent evaporation of formulation, covered with 
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Parafilm®. Samples of the receptor medium were collected at set time intervals over a period of 48 h and 
volumes extracted were replenished with the same volume of fresh medium. Samples were stored at 4◦C 
until analysis by HPLC (Section 2.10.). 
 
2.8. In vitro permeation studies; skin preparation and integrity tests 
In vitro permeation studies were carried out in the same manner as in vitro release studies 
(Section 2.7.), except new-born pig epidermis was used as the skin model. The new-born pig (3 weeks,~ 6 
kg) was obtained from the local slaughter house. Using the heat separation technique, the subcutaneous 
fat was sectioned off and the epidermis separated from the underlying dermis. The skin was immersed in 
60 ◦C hot water for 1 min and then the epidermal layer was gradually removed from the dermis. The 
epidermis sheets were cut into 2.5 cm x 2.5 cm pieces, wrapped in aluminium foil and stored at 20 ◦C 
until used. One day prior to conducting the studies, frozen skin pieces were thawed and placed in PBS 
(pH 7.4) to be hydrated overnight in the refrigerator (~ 4 ◦C). Before starting the studies, skin integrity 
was checked using a VapoMeter® (Delfin Technologies Ltd, Kuopio, Finland) to measure the 
transepidermal water loss (TEWL). Only skin samples with TEWL values of less than 15 g/m2.h were 
used in studies. Skin and sample preparation techniques used, complied with European guidelines (22).  
 
 
2.9. Calculations 
The cumulative amount of olanzapine diffused per unit area of skin (Qn) is given by; 
                                                     𝑄𝑛 = (𝐶𝑛  ×  𝑉0 + ∑  𝐶𝑖 ×  𝑉𝐼 
𝑛−1
𝑖=1
) /  𝐴                                             Eq. 4 
and is expressed in μg/cm2.This was plotted as a function of time (t, h). In Eq. (4), Cn corresponds to the 
drug concentration in the receptor medium at each sampling time, Ci is the drug concentration of the ith 
sample, A the effective diffusion area, V0 and Vi represent the volumes of the receptor compartment and 
the sample, respectively. The total quantities of the drugs obtained after 24 h (Q24) and 48 h (Q48) were 
used for comparison among formulations. The slope of the linear region of the plot; amount of drug 
permeated by unit area versus time, was used to calculate the flux at steady state. According to Fick's first 
law of diffusion, the flux (μg/cm2.h) can be expressed by; 
Jss = C0KD/L = C0Kp             Eq.5 
where C0 represents the drug concentration in the donor compartment, D is the diffusion coefficient, L the 
thickness of the membrane and K the partition coefficient of drug between membrane and vehicle. Kp 
stands for the permeability coefficient. The lag time (tlag) which relates to the amount of time required to 
achieve steady state flux of a drug through the skin, was estimated by extrapolation of the linear portion 
of the plot to the x-axis. 
7 
 
For release studies, only the cumulative percentage of drug was considered and plotted, using the 
same method as described above for permeation studies. 
 
2.10. HPLC determination of olanzapine 
HPLC analysis was performed using a Shimadzu apparatus (Shimadzu Co., Kyoto, Japan) 
equipped with a quaternary pump (LC-20AD), a degasser unit (DGU-20A5), an auto-sampler (SIL-20HT), 
an oven (CTO-10AS) and an UV/VIS photodiode array detector (SPD-M2OA). A Luna Phenyl-Hexyl (5 
μm; 150 mm x 3 mm) Phenomenex (USA) analytical column was used for analysis. The mobile phase 
consisted of ammonium acetate (0.02M in water): methanol: acetonitrile in the ratio 30:35:35 (V/V/V) 
and was set at a constant flow rate of 0.8 mL/min. A run time of 4 min was established and detection was 
carried out at 230 nm. A10 μL injection volume was used for each sample and calibration curve 
standards. Under these conditions, olanzapine was eluted at around 2 min. This method was previously 
validated (23).  
 
2.11. Stability studies 
The physical stability of the LN formulations was accessed using the LUMiFuge® (L.U.M. 
GmbH, Germany) stability analyser. This comprised an analytical centrifugation system, which measures 
the intensity of transmitted near infrared (NIR) light, over the total length of the cell, while the sample is 
being centrifuged. LUMiFuge® analysis allows attainment of an instability index value as well as 
transmission profiles, which enables comparison of phase separation and destabilization of formulations. 
The instability index is quantified by dividing the clarification of the sample at a given separation time, 
by the maximum sample clarification. Clarification quantifies the resultant increase in transmission, due 
to phase separation by creaming and flocculation. The instability index is a dimensionless number 
between 0-1, where “0” means no changes in particle concentration (stable formulation) and “1” means 
the dispersion has completely phase separated (unstable formulation). Thus, low values indicate greater 
physical stability (24, 25). 
Transmission profiles, unlike instability índex values, are displayed in real time as a function of 
radial position, allowing study of the formulation characteristics with respect to time. Analysis of changes 
in light transmission and movements in phase boundaries, allows comparisons in separation behaviour of 
formulations. Formulation stability was analysed after 210 min centrifugation, at a speed of 2300 x g at 
25 ◦C. 
 
2.12. Statistical analysis 
Statistical significances were evaluated using student t-test. A value of p<0.05 was considered 
significant. This analysis was performed using Microsoft Excel® (Microsoft®Excel®, version 14.5.1) 
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3. Results & discussion 
The development of a suitable nanocarrier system as a strategy to promote the transdermal 
delivery of olanzapine is described. This included the selection of an appropriate nanoparticle lipid 
matrix, the characterization and assessment of the nanosystem in terms of physicochemical, performance 
and stability. Preliminary screening solubility studies were performed for the selection of the solid lipid. 
 
3.1. Selection of solid lipid 
From Table 3, it can be seen that Precirol®-based nanoparticles exhibited the smallest size, 
followed by Compritol® and lastly stearic acid. NLC particle sizes usually range between 40-1,000 nm, 
where smaller particle sizes are generally most desirable (8). It should be noted that a smaller particle size 
leads to greater surface area contact between the NLC and skin surface, allowing for a higher drug 
absorption rate through the skin and, in turn, greater efficacy as a transdermal drug delivery system 
(TDDS) (17). A low polydispersity index value is desirable, as it means that the formulation is more 
homogenous. PI values range from 0 (monodisperse) to 0.5 (very broad distribution), where values less 
than 0.1 indicate high homogeneity and a narrow size distribution, making them optimal for TDDS (26). 
From Table 3, it can be seen that PI values were very similar. In general, PI values of less than 0.3 are 
considered optimal for the particle dispersion and homogeneity of such nanoparticles (27). 
 
Table 3. Characterisation of 50:50 ratio, solid: liquid lipid NLC with varying solid lipid. Key: PI: 
Polydispersity index, F: Occlusion factor; where F24h and F48 are the occlusion factors at 24 and 48 
hours, respectively. Results are expressed as mean± SD (n=9) 
a p<0.05 vs. Precirol®, b p<0.05 vs. Compritol® 
The F values at 24 h and 48 h did not vary significantly. A high occlusive effect is desirable, as 
this will result in lower transepidermal water loss, where the resulting hydration effect, leads to 
disorganisation of corneocyte packing within the stratum corneum (28). This has a direct effect on 
percutaneous absorption and improves drug permeation through the skin, once released from the drug 
dosage form (29). The results (Table 3) are in agreement with Müller et al. (30) study, where it was found 
that NLCs with smaller particle size, tend to have greater occlusive effect due to their tight packing and 
Formulation 
Hydrodynamic 
diameter (nm) 
PI 
Zeta potential   
(mV) 
F 24h F 48h 
Precirol® 209.17 ± 2.93b 0.295 ± 0.008 -29.58± 2.10 63.54±1.18 63.62±2.68 
Compritol® 290.34± 28.84a 0.299 ± 0.013 -28.91±0.89 59.99±1.84 55.97±3.81 
Stearic acid 396.52± 7.23a,b 0.330± 0.016 -32.89±1.18b 61.59±1.77 59.59±1.80 
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greater particle surface – skin contact, forming a film which inhibits evaporation from the skin surface 
(31). 
Zeta potential was also used as a selection parameter; in general, zeta potential values of -30 mV 
or less are desirable in nanoparticle production, resulting in high physical stability (17). All formulations 
had very similar zeta potential values, approximating -30 mV; thus, making them suitable for nanoparticle 
preparation, as the repulsion between the charged particles prevents aggregation (32). 
Taking all these physicochemical parameters into consideration, it was concluded that Precirol® 
was the most suitable solid lipid to progress with further investigations, as it exhibited the most promising 
properties to ensure the drug penetration through the skin: it allowed for production of small 
nanoparticles, which had a relatively tight size distribution and were physically stable. Additionally, 
olanzapine incorporated in nanoparticles using Precirol®, would be subjected to a lower termal stress due 
to its lower melting point (53–56 ◦C), compared to Compritol® and stearic acid. 
 
3.2. Evaluation of the influence of solid:liquid lipid ratio 
In general, as the ratio of solid:liquid lipid decreased, the mean particle size of the lipid 
nanocarriers tended to decrease (Table 4). This behaviour was more evident for unloaded nanoparticles. 
These findings are in agreement with the majority of existing literature and can be attributed to a lower 
viscosity of the dispersed phase (8). The same trend was observed for PI values, indicating greater 
formulation homogeneity as the proportion of liquid lipid is increased. 
With regards to zeta potential, as the solid:liquid lipid ratio decreased, more negative zeta 
potential values were obtained. Irrespective of the presence of olanzapine, all the formulations except 
LN100:0 can be considered stable, since they usually tend to be close to or lower than -30 mV. Such 
behaviour could be attributed to the inclusion of oleic acid. This is contradictory to Arts et al. (33) 
findings, where the addition of oleic acid resulted in a slight increase in zeta potential values. It should be 
noted that incorporation of olanzapine within the LN 100:0 formulation, produced stable OL-LN 100:0 
nanoparticles, with a zeta potential value of approximately -30 mV (17). 
From Table 4, it can be seen that for the different solid: liquid lipid ratios, as the amount of 
liquid lipid was increased the occlusive effect decreased. This is in agreement with Souto et al. (34), who 
when comparing NLC with varying liquid lipid content concluded that an increase in liquid lipid content 
led to a decrease of the occlusive factor. Thus, as mean particle size of LNs decreased so did the 
respective occlusive factor; this is in contradiction with the findings in Table 3. An explanation for this 
could be related to the degree of crystallinity of the lipid nanoparticles (35). The greater crystallinity 
would result in the formation of a tightly packed dense film, which would intrinsically prevent 
transepidermal water loss to a greater degree. Such a behaviour could be attributed to the direct influence 
of the different solid lipid content of the formulations.  
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Table 4. Characterisation of olanzapine-loaded and unloaded lipid nanocarrier formulations of varying 
Precirol®:oleic acid composition. Key: PI: Polydispersity index, EE: Entrapment efficiency, DL: Drug 
loading, F: Occlusion factor; where F 24h and F48h are the occlusion factors at 24 and 48 hours, 
respectively; OL = Olanzapine, LN = Lipid nanocarriers, OL-LN = Olanzapine loaded lipid nanocarrier 
formulation. Results are expressed as mean± SD (n = 9).  
a p<0.05 vs. LN 100:0, b p<0.05 vs. OL-LN 100:0, c p<0.05 vs. corresponding LN 
 
3.2.1. Entrapment efficiency and drug loading 
The solubility of olanzapine is known to be higher in oleic acid than in Precirol®, so it is likely, 
that as the amount of liquid lipid incorporated is increased so would the entrapment efficiency and 
consequent drug loading (8). 
Table 4 however, shows no significant difference in entrapment efficiency between the different 
nanoparticle formulations, suggesting that the inclusion of liquid lipid allows no significant increase in 
entrapment efficiency. A possible explanation for this is that the amount of olanzapine used was below 
the saturation limit, in that the lipid matrix had not reached its maximum drug loading capacity for EE 
differences to become apparent (7). 
Formulation 
solid: liquid 
lipid ratio 
Hydrodynamic 
diameter (nm) 
PI 
Zeta potential 
(mV) 
EE (%) DL (%) F 24h F 48h 
UNLOADED FORMULATIONS 
LN 100:0 653.60±72.73 0.351±0.023 -20.95±0.42  - - - 
LN75:25 347.45±39.30a 0.297 ± 0.014 -29.40±1.96a - - - - 
LN 50:50 209.17±2.93a 0.295±0.008 -29.58±2.10a - - - - 
LN25:75 157.27±3.20a 0.249± 0.006 -36.45±2.36a - - - - 
LN 0:100 155.35±4.14a 0.207 ± 0.014 -40.75±3.35a - - - - 
OLANZAPINE-LOADED FORMULATIONS 
OL-LN 100:0 509.19±78.56c 0.316±0.041 -28.77±1.73c 94.56±3.58 2.60±0.17 59.60±2.87 64.91±0.34 
OL-LN 75:25 454.91±35.08b,c 0.281±0.036 -31.34±1.62b,c 97.25±1.60 2.72±0.81 59.25±1.08 64.88±0.43 
OL-LN 50:50 194.30±14.38b,c 0.290±0.020 -30.51±3.31 98.28±1.16 2.86±0.25 54.81±1.10 59.04±2.10 
OL-LN 25:75 174.00±6.92b,c 0.239±0.012 -32.88±1.55b,c 98.52±1.04 2.77±0.22 43.31±2.85 43.21±2.35 
OL-LN 0:100 165.24±4.32b,c 0.214±0.033 -39.68±2.57b 97.89±0.40 3.01±0.40 40.80±2.89 35.22±2.27 
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The overall entrapment efficiencies of all formulations were between 97 and 98%. This 
confirmed that the drug dissolved in lipid matrix, remained associated with the matrix and that there was 
no drug diffusion (36).  
 
 
3.3. In vitro release studies 
Release studies give a preliminary indication to release behaviour of the drug from the 
formulation, in the absence of the main biological barrier, the stratum corneum. Release from the LNs 
depends on the partitioning of olanzapine within the lipid matrix and the subsequent rate of diffusion 
from the dialysis membrane. 
Fig.1 shows that in general, as the liquid lipid ratio is increased the release of olanzapine is 
slower. The solid lipid nanoparticle formulation is an exception to this; such behaviour could be attributed 
to its greater particle size (Table 4), that may have decreased drug diffusion from the nanoparticle 
surface. 
 
 
Fig. 1. In vitro release profiles of olanzapine-loaded LNs (OL-LN), of varying solid:liquid lipid 
composition. Release medium composed of 70% PBS (pH=7.4) and 30% ethanol. The results are 
expressed as mean ± SD (n = 6); * p<0.05 vs. OL-LN 100:0.  
 
It should be noted that although SLN formulations did not produce the fastest release profile, 
results are significantly faster than previous release studies (34). Such behaviour could be attributed to the 
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production of SLN type ΙΙ nanocarriers, which are referred to as the drug enriched shell model (15, 29). 
This model is additionally supported by the more negative zeta potential values obtained after olanzapine 
incorporation into 100:0 LN formulations (Table 4), indicating drug disposition at the surface of the 
nanoparticle (9). 
Despite OL-LN 0:100 and OL-LN 25:75 formulations having a greater proportion of liquid lipid 
and a resultant smaller particle size, they produced the slowest release profiles. This may be due to 
olanzapine having a greater solubility in oleic acid; the favourable lipophilic conditions within the 
nanoparticle may have impeded partitioning of olanzapine, from the lipophilic environment within the 
nanolipid matrix, to the external aqueous medium (28). In this instance, the solubility of olanzapine into 
oleic acid, dominates over the effects of particle size. 
Although the diffusion of a drug is usually more limited in a solid matrix in comparison to a 
liquid matrix, the dominant effect is the high solubility of olanzapine in oleic acid, which imparts a low 
partition between the oil and aqueous phase. 
All formulations exhibited initial burst release followed by a sustained release. The initial burst 
release is likely to be due to drug adsorbed on the nanoparticle surface and sustained release due to 
diffusion of drug from the lipid matrix (7). 
3.4. In vitro permeation studies 
In vitro permeation studies allow mimicking of physiological and anatomical conditions, to 
measure drug permeation across a membrane; being an important step in the TDDS development. 
Permeation studies consider the release of the drug from the lipid nanocarriers followed by penetration of 
the permeant into the stratum corneum. Release behaviour cannot, however, be directly related with 
permeation, as this considers the additional barrier of the stratum corneum (8). This is illustrated when 
comparing Fig. 1 and Fig. 2. 
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Fig. 2. In vitro permeation profiles of olanzapine-loaded LN (OL-LN), of varying solid:liquid 
lipid composition. Permaetion medium composed of 70% PBS (pH=7.4) and 30% ethanol. The results are 
expressed as mean ± SD (n = 8), * p<0.05 vs. OL-LN 100:0. 
Particles with a higher proportion of solid lipid (OL-LN 100:0 and OL-LN 75:25), presented the 
fastest flux, in particular the SLNs (Fig. 2). This is in concordance with occlusive factor results (Table 4) 
and release studies (Fig. 1). Additionally, this corroborates the previous model suggested for the structure 
of SLN type II. This has already been observed by Teeranachaideekul et al. (35), where SLNs were found 
to provide a greater occlusive effect due to their greater crystallinity, which allows formation of a thin 
occlusive film that prevents transepidermal water loss. The greater water retention, increases inter-
corneocyte gaps, providing a more disorganised structure of the stratum corneum, enhancing drug 
permeation. 
Permeation parameters derived from the permeation studies are shown in Table 5. SLN 
formulation had the highest flux and permeability coefficient, which gave rise to greater Q24 and Q48 
values. 
Table 5. Formulations and respective permeation parameters of olanzapine-loaded LNs (OL-LN). Key: 
JSS = Flux at steady-state, Kp = Permeability coefficient, tlag = lag time, Q24 and Q48 = Cumulative 
amount of olanzapine permeated after 24 h and 48 h, respectively. Data are expressed as mean ± SD (n = 
8).
Formulation Jss(µg/cm2.h) Kp (cm/h)(x 10 -3) tlag (hr) Q24 (µg/cm2) Q48 (µg/cm2) 
OL-LN100:0 2.47 ± 0.885 1.17 ± 0.40 17.89± 2.12 17.01± 7.00 73.67 ± 25.60 
OL-LN 75:25 0.49 ± 0.23a 0.22 ± 0.10a 18.76 ± 2.54 3.24 ± 2.32a 14.83 ± 6.29a 
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a p<0.05 vs. OL-LN 100:0 
 
Oleic acid is thought to disrupt packing within the stratum corneum and act as a chemical 
penetration enhancer (CPE) (37). The long chained CPE interacts with lipid chains, forming pools in the 
skin known as fluidization, which allows the drug to diffuse faster between inter-corneocyte gaps (38). 
Despite having no oleic acid, SLN formulations had the fastest permeation rate (Fig. 2). This could be 
due to its greater occlusive effects (Table 4), which result in greater percutaneous absorption. 
According to current olanzapine dosing regimen, a daily dose of 5-10 mg is required to achieve 
therapeutic effect. Since oral bioavailability of olanzapine is ca. 60%, the estimated transdermal dose to 
obtain therapeutic effects is 3-6 mg per day (8). Thus, the target transdermal flux based on in vitro 
permeation studies should be between 3.1-6.2 μg/cm2.h, considering a 40 cm2 patch size. This yields an 
amount permeated per day of 75-150 μg/cm2. The in vitro results obtained are all below transdermal 
target values. Considering the SLN formulation with the highest flux, a fine-tuning of formulation could 
allow achievement of target therapeutic doses. For example, by the increase in lipid concentration, or by 
the incorporation of chemical enhancers in the aqueous phase of SLN (39). 
Sustained release formulations are desirable for olanzapine delivery, to allow a constant 
therapeutic delivery. A doubling in Q24 value for Q48 value, would indicate sustained release. 
Comparing Q24 and Q48 values in Table 5 however, it can be seen that this was not the case and that 
sustained release formulations were not produced.  
Considering tlag values, although they were generally high they do not represent an issue as we 
are dealing clinically with chronic conditions, where therapeutic doses are maintained between new 
doses. 
 
3.5. Stability studies 
3.5.1. Instability index 
Instability values are a good indicator of long-term storage stability. According to Fig. 3, 
formulations with low oleic acid content would be best in long-term storage. 
 
OL-LN 50:50 0.18±0.12a 0.087 ± 0.06a - 1.35 ± 1.24a 1.89 ± 1.40a 
OL-LN 25:75 0.58±0.93a 0.294 ± 0.01a - 5.78 ± 5.65a 6.26 ± 5.07a 
OL-LN 0:100 0.02 ± 0.01a 0.011± 0.01a - 6.98 ± 2.17a 8.63 ± 3.35a 
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Fig. 3. Instability index values for various solid:liquid lipid formulations, generated via LUMiFuge 
analysis. Lower values are indicative of formulations having greater stability. 
 
It can be noticed that conversely to zeta potential values, in general as the amount of liquid lipid 
incorporated into the nanolipid system increased, so did nanolipid instability. Unloaded and loaded 0:100 
formulations were the most unstable. Such a trend has been reported previously (40). 
Incorporation of olanzapine did not promote a significant change in stability of the formulations. 
This is generally in agreement with particle size results (Table 4). 
Particle size, surface charge and the percentage lipid ratio, are thought to affect the overall 
stability of the nanocarrier system. Generally, a higher particle size is found to correlate with formulation 
viscosity and an increase in the rate of particle aggregation. Surface charge is considered a key factor 
contributing to stability of the nanocarrier (32). 
 
3.5.2. Transmission profiles 
Transmission profiles in Fig. 4 are taken over time, throughout the length of the sample and 
represent potential phase separation within the different formulations. Differences in transmission 
throughout a sample, allow estimation of the extent of flocculation or creaming present, if at all. Red 
profiles represent earlier profiles and green profiles represent the last profiles. Transmission profiles are 
in agreement with instability data (Fig. 3), formulations with a high liquid lipid content are less stable. 
Comparing Fig. 4(a) with Fig. 4(e), a pronounced difference was observed. Fig.4 (e) shows creaming and 
flocculation within the OL-LN 0:100 formulation over time, whilst subjected to centrifugation. This is 
indicated by the greater transmission values, towards the bottom of the sample (right hand side of figure) 
and relatively lower transmission values at the top of the sample. The relatively lower transmission values 
indicate regions of lower clarity, as less NIR light is able to pass through and be detected, these regions 
indicate; aggregation of particles resulting in flocculation and creaming at the top. In contrast, SLN 
formulation (Fig. 4(a)) remained intact and showed no significant signs of separation, demonstrating 
higher physical stability. 
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(e) 
Fig.4. Transmission profiles for various solid:liquid lipid formulations generated via LUMiFuge analysis. 
(a) OL-LN 100:0, (b) OL-LN 75:25, (c) OL-LN 50:50, (d) OL-LN 25:75 and (e) OL-LN 0:100. The 
sequence of profiles is shown from the bottom (red), for the first profiles, to the top (green) for the last 
profiles.  
 
Regarding the transmission profiles, greater phase separation was exhibited with formulations of 
greater liquid lipid content. This in in agreement with Vitorino et al. findings, where it is expected that 
with an increase of the liquid lipid a more unstable system would be obtained (coalescence tends to occur 
with a lower solid content) (9). 
 
4. Conclusion 
The study has demonstrated successful production of various solid:liquid lipid ratio nanocarriers, 
where Precirol® was found to be the most efficient solid lipid of those tested. This was based on the low 
particle size attained for the NLCs, combined with the analysis of other selection parameters. In vitro 
performance of formulations along with their characterisation, allowed selection of SLNs as the most 
appropriate choice for transdermal drug delivery of olanzapine. SLN formulations performed well in the 
majority of physicochemical parameters. They exhibited good physical stability, greatest occlusive effect, 
a relatively fast release rate and the highest flux. The present work shows that SLNs are a promising 
nanocarrier system for transdermal delivery of olanzapine. Optimisation of SLNs is however required 
such as obtaining a lower PI, which would allow greater control on TDDS in terms of release. Fine-tuning 
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of the formulation, to reach a target flux would also be required, so that an effective therapeutic dose of 
olanzapine is administered. Although the SLNs performed well in stability studies, long-term storage 
studies over a period of six months would also be needed. Future prospects include formulation of the 
SLN into reservoir system-transdermal patches, for effective olanzapine delivery.  
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